Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), retaining the price target of $20.00.

Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Abeona Therapeutics’ promising financial and strategic position. The recent sale of the Rare Pediatric Disease Priority Review Voucher for $155 million provides Abeona with a substantial cash runway, allowing the company to cover its operating expenses for over two years without needing additional capital. This financial stability is further bolstered by the anticipated cash inflow from the sales of ZEVASKYN, which was approved by the FDA in April 2025.
Furthermore, Abeona’s strategic initiatives, such as the planned treatment of patients with pz-cel and the establishment of qualified treatment centers, position the company for significant market penetration in treating recessive dystrophic epidermolysis bullosa. The expected revenue from ZEVASKYN sales, alongside potential royalties from future products like UX111, supports a strong growth trajectory. Abeona’s management anticipates achieving profitability by early 2026, with potential for earlier profitability depending on the success of ZEVASKYN’s launch, making the stock an attractive investment opportunity.

According to TipRanks, Selvaraju is a 4-star analyst with an average return of 7.7% and a 37.70% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Niagen Bioscience, and Vanda.

In another report released on April 29, Stifel Nicolaus also maintained a Buy rating on the stock with a $21.00 price target.